2104-P: Characteristics of Automated Insulin Delivery (AID) User Profiles in Young Adults (YAs) with Type 1 Diabetes

Introduction and Objective: YAs experience many life changes that impact diabetes self-care. In an era of increasing AID use, it is timely to study the interplay of AID use, sociodemographic factors, and glycemic control in this vulnerable age group. Methods: Electronic health record data from 2022-23 were reviewed for YAs with T1D at a tertiary center. YAs ages 18-24 at 1st visit were followed until age 26 or the end of 2023. Each visit was assessed qualitatively for consistency of AID use and reported reasons for AID use/non-use. We created User Profiles based on dominant AID use patterns: 1) Consistent Users, 2) Inconsistent Users, 3) Discontinuers, and 4) Never Users. Sociodemographic characteristics, glycemic outcomes from YAs' most recent visit, and reported reasons for AID use/non-use were compared among User Profiles. Results: Data included 1142 YAs (age 22.6±2.1y, T1D duration 13.0±5.8y, 50% male, 92% on private insurance, 91% CGM users, 73% pump users, A1c 7.6±1.4%). Notable differences emerged in characteristics and glycemic outcomes based on AID user profiles (Table). AID non-users most often endorsed personal reluctance to use AID; Inconsistent Users most often reported supply issues and challenges staying in automode. Conclusion: Differences among AID user profiles indicate suboptimal glycemia and health parity challenges in those not using AID. Future research should investigate potential barriers to AID use and strategies to support consistent use. Disclosure P.V. Commissariat: None. L.J. Tinsley: None. M.C. Penman: None. G. Orloff: None. A. Adam: None. L.M. Laffel: Other - Travel support for scientific presentations; Ended; Boehringer Ingelheim International GmbH. Other - DSMB Chair; Ended; Janssen Pharmaceuticals, Inc. Consultant; Current; Dexcom, Inc. Advisory Panel; Current; Medtronic, Sequel, Tandem Diabetes Care, Inc. Consultant; Current; Roche Diabetes Care, Sinocare. Advisory Panel; Ended; Sanofi. Advisory Panel; Current; MannKind Corporation. Funding National Institutes of Health (K23DK137024)